Clinical Trial: A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

U.S., Oct. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07221227) titled 'A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH' on Oct. 15.

Brief Summary: The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcome compared to placebo in individuals with MASH and biopsy-confirmed F2- or F3-stage fibrosis.

Study Start Date: Oct. 16

Study Type: INTERVENTIONAL

Condition: Non-alcoholic Fatty Liver Disease

Intervention: DRUG: Efimosfermin alfa

Efimosfermin alfa will be administered

DRUG: Efimosfermin alfa

Efimosfermin alfa will b...